Liver Diseases  >>  ViraferonPeg (peginterferon-α-2b)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

18 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
480S, NCT00953589 / 2009-011182-86: 480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)

Completed
2b
74
Europe, RoW
ribavirin, Ribasphere
Biolex Therapeutics, Inc.
Hepatitis C, Chronic
05/10
01/11
SELECT-2, NCT00863239 / 2008-007649-30: Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV

Checkmark DDW 2012
Apr 2011 - Apr 2011: DDW 2012
Checkmark EASL 2012
Mar 2011 - Mar 2011: EASL 2012
Completed
2b
116
US, Europe
ribavirin, Ribasphere®, Locteron™ (controlled-release interferon alpha 2b), Locteron, PolyActive, BLX-883, PEG-Intron™, 12 kDalton pegylated interferon
Biolex Therapeutics, Inc.
Hepatitis C, Chronic
11/10
11/11
NCT00959699 / 2008-004864-38: A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

Checkmark
Jun 2013 - Jun 2013: 
Completed
2b
99
NA
PegIFN-2b, SCH 054031, MK-4031, Pegylated interferon alfa-2b, Peginterferon alfa-2b, RBV, Ribavirin, Placebo to Boceprevir, Boceprevir, SCH 503034, MK-3034, Victrelis
Merck Sharp & Dohme LLC
HIV Infections, Hepatitis C, HCV Infection
05/12
10/12
NCT00528528 / 2007-001044-44: An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Completed
2a
166
Europe
Telaprevir, Peg-IFN-alfa-2a, Peg-IFN-alfa-2b, Ribavirin (RBV) tablet, Ribavirin (RBV) capsule
Tibotec BVBA
Chronic Hepatitis C
07/09
08/09
NCT01016912: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

Checkmark
Jan 2014 - Jan 2014: 
Checkmark
Jan 2014 - Jan 2014: 
Checkmark Data-AASLD
More
Completed
2a
51
Japan
BMS-790052, Placebo, Peginterferon alfa-2b, PegIntron®, Ribavirin, Rebetol®
Bristol-Myers Squibb
Hepatitis C Infection
09/10
09/10
NCT00787371: Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)

Completed
2
69
NA
PegIntron (peginterferon alfa-2b), PegIntron, peginterferon alfa-2b, SCH 54031
Merck Sharp & Dohme LLC
Hepatitis C, Chronic, Hepatitis C
07/06
07/06
NCT00160251 / 2005-001264-31: Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)

Completed
2
357
US
Boceprevir (BOC), SCH 503034, PegIntron (PEG), Ribavirin (RBV)
Merck Sharp & Dohme LLC
Chronic Hepatitis C
07/07
07/07
NCT00367887: A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

Completed
2
246
US
Peg-Intron, REBETOL, HCV 796
Wyeth is now a wholly owned subsidiary of Pfizer, ViroPharma
Hepatitis C
07/08
07/08
NCT00423670 / 2006-002543-92: Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)

Completed
2
765
NA
boceprevir (SCH 503034), Boceprevir, Victrelis, SCH 503034, peginterferon-alfa 2b (PegIntron), ribavirin, ribavirin (low-dose)
Merck Sharp & Dohme LLC
Chronic Hepatitis C
08/08
11/08
HEPCPR, NCT00018031: Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients

Completed
2
36
US
Peginterferon alfa-2b, PegIntron, PEG-Intron, PegIntron Redipen, Sylatron, Ribavirin, ICN-1229, Copegus, Rebetol, Ribasphere, RBV, RTCA, Rebretron, Ribav, Ribavirine, Tribavirin, Vilona, Viramid, Virazid, Virazole, CAS Number: 36791-04-5
National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, HIV Infections
04/09
04/09
NEXT-1, NCT00797745: A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)

Checkmark AASLD 2011
Oct 2011 - Oct 2011: AASLD 2011
Completed
2
111
US
peginterferon alfa 2b, PegIntron, ribavirin, REBETOL, SCH 900518, ritonavir, Norvir
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
07/09
09/10
TCM-700C, NCT00556504: The Effects of Adding on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection

Completed
2
84
RoW
TCM-700C, Peginterferon alfa-2a, Peg-INTRON, Schering-Plough, Ribavirin, Rebetol, Schering-Plough), Placebo
TCM Biotech International Corp.
Chronic Hepatitis C
01/11
05/11
NCT00588146: Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia

Terminated
2
10
US
Pegylated Interferon Alpha2b, PEG-Intron, Standard care
Mayo Clinic, Augusta University, Unity Health Toronto, Schering-Plough
Anemia, Liver Disease, Hypoxemia
09/11
09/11
NCT01440595 / 2011-003299-36: Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

Terminated
2
5
NA
Grazoprevir, MK-5172, Placebo to Grazoprevir, Peginterferon alfa-2b (Peg-IFN), PegIntron®, SCH 054031, Ribavirin (RBV), Rebetol®, SCH 018908
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
05/12
05/12
NCT01353911 / 2011-000759-18: Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

Checkmark
Apr 2014 - Apr 2014: 
Checkmark IWCPHT 2013
Jul 2013 - Jul 2013: IWCPHT 2013
Checkmark APASL 2013
More
Completed
2
368
NA
Grazoprevir, Boceprevir, Victrelis, Placebo for Grazoprevir, Placebo for Boceprevir, Peg-interferon alfa-2b, PegIntron, Peg-IFN alfa-2b, Ribavirin, Rebetol
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
01/13
03/15
NCT00059358: Zidovudine Levels in HIV Infected Patients Being Treated for HCV

Completed
1/2
16
US
Ribavirin plus interferon alfa-2b, Ribavirin, Peginterferon alfa-2b
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Hepatitis C
06/05
06/05
PLUS, NCT00593151: Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

Completed
1/2
32
US
Locteron (controlled-release interferon alpha 2b), PolyActive-IFNa2b, BLX-883+PolyActive, pegylated IFNa2b, PEG-Intron, PEG, 12 kDalton pegylated interferon alpha 2b
Biolex Therapeutics, Inc.
Hepatitis C
12/08
03/09
NCT01701063 / 2011-004564-30: An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

Terminated
1/2
42
US, Europe
Telaprevir, Peginterferon alfa-2b, PegIntron®, Ribavirin, Rebetol®
Vertex Pharmaceuticals Incorporated, Janssen Pharmaceuticals
Hepatitis C
04/15
04/15

Download Options